Amgen

EMA Tightens Liver Safety Checks for Tavneos After Fatal Cases

EMA · vasculitis · 5 min

EMA's PRAC has tightened monitoring and stopping rules for Tavneos (avacopan) after reviewing serious liver injury cases, including fatal outcomes. The update adds liver injury as a rare side effect and creates a new regulatory watchpoint for Amgen and ANCA-associated vasculitis teams.

MariTide Phase 2 obesity data show up to 20% weight loss at one year

obesity · 5 min

Amgen’s MariTide phase 2 obesity data showed up to 20% average weight loss at 52 weeks in participants without type 2 diabetes. The trial also reported up to 17% average weight loss in participants with type 2 diabetes, with placebo results provided in the published data.

MariTide Phase 2: Amgen reports up to 20% weight loss at one year

obesity · 5 min

Amgen’s MariTide Phase 2 obesity study reported up to ~20% average weight loss at one year in participants without type 2 diabetes and up to ~17% in those with type 2 diabetes. The plan below focuses only on the trial facts, the placebo comparisons, and the clinical-trial readouts already supported by source material.

Amgen Inc Stock: Lung Cancer Setback Meets Steady Cash Flow

lung cancer · 3 min

Amgen Inc faces a setback in lung cancer trials but maintains strong cash flow. This article explores its implications for investors and pharma teams.